UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.289

Sortiert nach

Combination therapy with PD-1 or PD-L1 inhibitors for cancer

International journal of clinical oncology, 2020-05, Vol.25 (5), p.818-830

2020

Link zum Volltext

Verfügbarkeit prüfen

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Nature medicine, 2020-01, Vol.26 (1), p.47-51

2020

Link zum Volltext

Verfügbarkeit prüfen

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

Clinical cancer research, 2018-06, Vol.24 (11), p.2653-2664

2018

Link zum Volltext

Verfügbarkeit prüfen

Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer

Clinical cancer research, 2020-04, Vol.26 (8), p.2037-2046

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR -Mutated Non-Small Cell Lung Cancer

Cancer discovery, 2022-01, Vol.12 (1), p.74-89

2022

Link zum Volltext

Verfügbarkeit prüfen

Lysine-Specific Demethylase 1 (LSD1/KDM1A) Is a Novel Target Gene of c-Myc

Biological and Pharmaceutical Bulletin, 2019/03/01, Vol.42(3), pp.481-488

2019

Link zum Volltext

Verfügbarkeit prüfen

Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?

BMC medicine, 2020-04, Vol.18 (1), p.111-111, Article 111

2020

Link zum Volltext

Verfügbarkeit prüfen

Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer

Cancer science, 2019-01, Vol.110 (1), p.52-60

2019

Link zum Volltext

Verfügbarkeit prüfen

Pseudokinase Tribbles 1 (TRB1) Negatively Regulates Tumor-Suppressor Activity of p53 through p53 Deacetylation

Biological and Pharmaceutical Bulletin, 2015/04/01, Vol.38(4), pp.618-624

2015

Link zum Volltext

Verfügbarkeit prüfen

Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts

British journal of cancer, 2021-03, Vol.124 (5), p.914-924

2021

Link zum Volltext

Verfügbarkeit prüfen

Real-World Clinical Outcomes after Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer

Current oncology (Toronto), 2022-07, Vol.29 (7), p.4811-4826

2022

Link zum Volltext

Verfügbarkeit prüfen

TRB1 negatively regulates gluconeogenesis by suppressing the transcriptional activity of FOXO1

FEBS letters, 2019-02, Vol.593 (3), p.369-380

2019

Link zum Volltext

Verfügbarkeit prüfen

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer

Future oncology (London, England), 2022-02, Vol.18 (6), p.639-647

2022

Link zum Volltext

Verfügbarkeit prüfen

Synthesis of Morita–Baylis–Hillman-fluorides using 1,1,2,2-tetrafluoroethyl-N,N-dimethylamine

Tetrahedron, 2021-09, Vol.97, p.132387, Article 132387

2021

Link zum Volltext

Verfügbarkeit prüfen

HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer

Clinical cancer research, 2022-01, Vol.28 (2), p.390-403

2022

Link zum Volltext

Verfügbarkeit prüfen

First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis

International journal of clinical oncology, 2021-06, Vol.26 (6), p.1073-1082

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease

Scientific reports, 2021-04, Vol.11 (1), p.9242-9242, Article 9242

2021

Link zum Volltext

Verfügbarkeit prüfen

HMG-CoA Reductase Inhibitor Statins Activate the Transcriptional Activity of p53 by Regulating the Expression of TAZ

Pharmaceuticals (Basel, Switzerland), 2022-08, Vol.15 (8), p.1015

2022

Link zum Volltext

Verfügbarkeit prüfen

Suppressive effects of processed aconite root on dexamethasone-induced muscle ring finger protein-1 expression and its active ingredients

Journal of natural medicines, 2022-06, Vol.76 (3), p.594-604

2022

Link zum Volltext

Verfügbarkeit prüfen

The deubiquitinating enzyme USP17 regulates c‐Myc levels and controls cell proliferation and glycolysis

FEBS letters, 2022-02, Vol.596 (4), p.465-478

2022

Link zum Volltext

Verfügbarkeit prüfen

SET8 is a novel negative regulator of TGF-β signaling in a methylation-independent manner

Scientific reports, 2023-12, Vol.13 (1), p.22877-22877, Article 22877

2023

Link zum Volltext

Verfügbarkeit prüfen

PSY6-3 Site-prediction based on molecular profiling for CUP. Is this needed?

Annals of oncology, 2022-07, Vol.33, p.S421

Hayashi, Hidetoshi

2022

Link zum Volltext

Verfügbarkeit prüfen

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?

Cancer science, 2016-08, Vol.107 (8), p.1134-1140

2016

Link zum Volltext

Verfügbarkeit prüfen

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK―Positive Non―Small Cell Lung Cancer

Clinical cancer research, 2012-11, Vol.18 (22), p.6219-6226

2012

Link zum Volltext

Verfügbarkeit prüfen

The CDK inhibitor p21 is a novel target gene of ATF4 and contributes to cell survival under ER stress

FEBS letters, 2017-11, Vol.591 (21), p.3682-3691

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.289

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.046)
Mit Volltextzugriff
(1.211)

Publikationsform

Sprache

Englisch
(1.150)
Japanisch
(485)
Deutsch
(1)
Chinesisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(18)

Menü

Weitere Dienste

Einstellungen

Combination therapy with PD-1 or PD-L1 inhibitors for cancer

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR -Mutated Non-Small Cell Lung Cancer

Lysine-Specific Demethylase 1 (LSD1/KDM1A) Is a Novel Target Gene of c-Myc

Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?

Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer

Pseudokinase Tribbles 1 (TRB1) Negatively Regulates Tumor-Suppressor Activity of p53 through p53 Deacetylation

Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts

Real-World Clinical Outcomes after Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer

TRB1 negatively regulates gluconeogenesis by suppressing the transcriptional activity of FOXO1

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer

Synthesis of Morita–Baylis–Hillman-fluorides using 1,1,2,2-tetrafluoroethyl-N,N-dimethylamine

HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer

First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis

Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease

HMG-CoA Reductase Inhibitor Statins Activate the Transcriptional Activity of p53 by Regulating the Expression of TAZ

Suppressive effects of processed aconite root on dexamethasone-induced muscle ring finger protein-1 expression and its active ingredients

The deubiquitinating enzyme USP17 regulates c‐Myc levels and controls cell proliferation and glycolysis

SET8 is a novel negative regulator of TGF-β signaling in a methylation-independent manner

PSY6-3 Site-prediction based on molecular profiling for CUP. Is this needed?

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK―Positive Non―Small Cell Lung Cancer

The CDK inhibitor p21 is a novel target gene of ATF4 and contributes to cell survival under ER stress

Suchergebnisse filtern